Milestone broadens partnership to develop novel ocular thera…
News
July, 29 2021 • Articles
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
July 29th, 2021 - Source: Inside Philanthropy
Since its establishment in 1971 by a group of families affected by retinal disease, the Foundation Fighting Blindness has funded research into several of the most serious and common of these conditions, like macular degeneration and retinitis pigmentosa. The foundation grew to become the leading private funder of basic research into conditions that cause blindness and vision loss for more than 10 million Americans and millions more worldwide. In its 50 years in operation, the foundation has raised over $816 million to support research—including the identification of key genes linked to retinal diseases—that has enabled the launch of dozens of clinical trials to test possible treatments. All in all, a solid track record.
Click here for the rest of the article
OPGx-LCA5 is designed to address vision loss due to Leber co…
- Lead gene therapy asset, SPVN06, reported to be well-toler…
Amber Bio is developing a first-of-its-kind RNA writing plat…
Amber Bio’s proprietary platform leverages multi-kilobase RN…
Agreement provides ProQR with initial payment of €12.5M and …
New clinical site added and early safety signals observed in…
Dr. Léveillard helped discover and develop a gene-agnostic, …
Phase 1/2 SLO-RP trial completed target enrollment of 48 pat…
- First oral presentation on SPVN20 in a major scientific and…
ATSN-201 leverages AAV capsid that spreads laterally beyond …
Paris, April 27, 2023 – SparingVision (“the Company”), a cli…